EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 3.0

Real-world effectiveness and safety of vedolizumab induction therapy for ulcerative colitis: A prospective nationwide Polish observational study

Edyta Zagórowicz, Halina Cichoż-Lach, Maria Kopertowska-Majchrzak, Piotr Eder, Kamila Stawczyk-Eder, Renata Talar-Wojnarowska, Hubert Zatorski, Anna Solarska-Półchłopek, Rafał Filip, Maria Janiak, Krzysztof Skrobot, Maria Kłopocka und 5 weitere

Advances in Clinical and Experimental Medicine · 2023

DOI: 10.17219/acem/162969 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Advances in Clinical and Experimental Medicine, 2023. Verfasst von Edyta Zagórowicz und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncological Gastroenterology, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biological Products, Antibodies, Monoclonal, Humanized. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vedolizumab is recommended as a first-line biological treatment, along with other biological drugs, in ulcerative colitis (UC) patients in whom conventional therapy failed and as a second-line biological treatment following a failure of a tumor necrosis factor alpha (TNF-α) antagonist. OBJECTIVES: We aimed to assess the real-world effectiveness and safety of vedolizumab induction therapy in UC patients treated in the scope of the National Drug Program (NDP) in Poland. MATERIAL AND METHODS: The endpoints were the proportions of patients who reached clinical response, clinical remission and mucosal healing at week 14. Partial Mayo scores, Mayo subscores and C-reactive protein (CRP) levels were also evaluated. RESULTS: Our study population consisted of 100 patients (55 biologic-naïve and 45 biologic-exposed). The median total Mayo score at baseline was 10 (interquartile range (IQR): 9-11), and 52 patients (52%) had extensive colitis. The clinical response at week 14 was achieved in 83 (83%) and clinical remission in 24 (24%) cases. Mucosal healing was observed in 56 (62%) patients at week 14. In patients with prior failure of biologic treatment (n = 25), 17 (68%) responded to vedolizumab treatment. A decrease in the median CRP level (from 3.7 mg/L to 2.6 mg/L) and the median total Mayo score (from 10 to 4) was observed. No new safety concerns were recorded and no patients discontinued the treatment due to adverse events (AEs). CONCLUSIONS: Vedolizumab was effective and safe as induction therapy for UC in a Polish real-world population including patients with severely active UC and a low number of patients with prior biological treatment failures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeBiological ProductsAntibodies, Monoclonal, HumanizedHumansPolandProspective StudiesInduction ChemotherapyGastrointestinal AgentsTreatment OutcomeRemission Induction

Stichwörter der Autor:innen

National Drug Programinduction therapyreal-world evidenceulcerative colitisvedolizumab

Substanzen

vedolizumabGastrointestinal AgentsBiological ProductsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Oncological Gastroenterology, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, Warsaw, Poland.
  • Department of Gastroenterology, Medical University of Lublin, Poland.
  • Department of Internal Diseases, General Hospital, Międzychód, Poland.
  • Department of Gastroenterology, Dietetics and Internal Diseases, H. Święcicki University Hospital, Poznan University of Medical Sciences, Poland.
  • Department of Digestive Tract Diseases, Medical University of Lodz, Poland.

Zitieren

APA

Zagórowicz, E., Cichoż-Lach, H., Kopertowska-Majchrzak, M., Eder, P., Stawczyk-Eder, K., Talar-Wojnarowska, R., Zatorski, H., Solarska-Półchłopek, A., Filip, R., Janiak, M., Skrobot, K., Kłopocka, M., Liebert, A., Kaczka, A., Wojciechowski, K., Drygała, S., & Michalak, A. (2023). Real-world effectiveness and safety of vedolizumab induction therapy for ulcerative colitis: A prospective nationwide Polish observational study. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/162969

Vancouver

Zagórowicz E, Cichoż-Lach H, Kopertowska-Majchrzak M, Eder P, Stawczyk-Eder K, Talar-Wojnarowska R, et al. Real-world effectiveness and safety of vedolizumab induction therapy for ulcerative colitis: A prospective nationwide Polish observational study. Advances in Clinical and Experimental Medicine. 2023. doi:10.17219/acem/162969

BibTeX
@article{Zagrowicz2023,
  author = {Zagórowicz, Edyta and Cichoż-Lach, Halina and Kopertowska-Majchrzak, Maria and Eder, Piotr and Stawczyk-Eder, Kamila and Talar-Wojnarowska, Renata and Zatorski, Hubert and Solarska-Półchłopek, Anna and Filip, Rafał and Janiak, Maria and Skrobot, Krzysztof and Kłopocka, Maria and Liebert, Ariel and Kaczka, Aleksandra and Wojciechowski, Krzysztof and Drygała, Szymon and Michalak, Agata},
  title = {Real-world effectiveness and safety of vedolizumab induction therapy for ulcerative colitis: A prospective nationwide Polish observational study},
  journal = {Advances in Clinical and Experimental Medicine},
  year = {2023},
  doi = {10.17219/acem/162969}
}
Kostenlos starten →